Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?

Daniel Vis, Athénaïs Boucly, Marc Humbert, Jason Weatherald
European Respiratory Journal 2020 55: 2000700; DOI: 10.1183/13993003.00700-2020
Daniel Vis
1Dept of Medicine, Division of Respirology, University of Calgary, Calgary, AB, Canada
2Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athénaïs Boucly
3Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
4Assistance Publique - Hôpitaux de Paris (AP-HP), Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
5INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Humbert
3Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France
4Assistance Publique - Hôpitaux de Paris (AP-HP), Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
5INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marc Humbert
Jason Weatherald
1Dept of Medicine, Division of Respirology, University of Calgary, Calgary, AB, Canada
6Libin Cardiovascular Institute of Alberta, Calgary, AB, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jason Weatherald
  • For correspondence: jcweathe@ucalgary.ca
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Pre-capillary pulmonary hypertension is a rare and heterogenous complication in sarcoidosis. 6-min walking distance is a robust and consistent prognostic factor, but the role of pulmonary arterial hypertension-targeted treatments remains controversial. http://bit.ly/2J27Yps

Pulmonary hypertension (PH) is a well described and clinically important complication in sarcoidosis. The epidemiology of sarcoidosis-associated pulmonary hypertension (SaPH) varies depending on the characteristics of the population analysed, but ranges from 3–75%, depending on method of diagnosis (i.e. echocardiography versus right heart catheterisation (RHC)) and severity of underlying sarcoidosis [1–4]. Elevation of pulmonary arterial pressure in sarcoidosis can occur via a number of mechanisms (figure 1) [5, 6] and, as such, SaPH has remained under group 5 (PH with unclear and/or multifactorial mechanisms) in the recent 6th World Symposium on Pulmonary Hypertension [7]. The breadth of pathophysiologic mechanisms that lead to PH is fairly unique to sarcoidosis, which makes SaPH an interesting but complicated entity.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Multifactorial mechanisms lead to pulmonary hypertension (PH) in sarcoidosis, including hypoxic vasoconstriction, pulmonary vascular rarefaction, parenchymal destruction, left heart disease with post-capillary PH, portal hypertension from liver disease, pulmonary vascular remodelling, changes resembling pulmonary veno-occlusive disease (PVOD), and extrinsic vascular compression due to fibrosing mediastinitis or enlarged lymph nodes.

To date, due to the relative rarity of the condition and lack of multinational registries, there have been limited published data on large cohorts of SaPH patients to allow accurate understanding of the predictors of disease behaviour, clinical outcomes, and response to treatment. Due to the paucity of information available regarding the behaviour of this condition, large cohorts of SAPH patients have recently been described in order to enrich our understanding of the condition [3, 8, 9].

In 2005, Shorr et al. [3] presented a large cohort (n=363) of sarcoidosis patients listed for lung transplant. Patients with PH had higher oxygen requirements, greater functional limitation, and impaired cardiac function in comparison to sarcoidosis patients listed for transplant with mean pulmonary arterial pressure (mPAP) <25 mmHg. In 2017, Boucly et al. [8] published their series in the European Respiratory Journal with haemodynamic and clinical data from 126 patients with severe SaPH of pre-capillary origin (defined as pulmonary artery wedge pressure ≤15 mmHg, mPAP >35 mmHg, or mPAP 25–35 mmHg with cardiac index <2.5 L·min−1·m−2). Patients with presumed alternative aetiologies of pulmonary vascular disease, such as thromboembolic disease, HIV, connective tissue disease, congenital heart disease or exposure to drugs/toxins were excluded. This study demonstrated the importance of 6-min walk distance (6MWD) on transplant-free survival in multivariate analysis. Additionally, univariate analysis suggested the potential importance of lung function (transfer coefficient of the lung (KCO) and forced vital capacity (FVC)) and functional class, though these failed to remain as independent predictors. They also demonstrated a unique cohort of patients that had significant improvement with augmented immunosuppressive treatment, potentially identifying an important group of patients for whom treatment of the underlying condition may portend a better response than pulmonary arterial hypertension (PAH) treatment. With respect to PAH therapy in SaPH, limited randomised trial data are available, consisting of a single study performed utilising bosentan by Baughman et al. [10], which demonstrated small improvements in haemodynamics on RHC, without changes in 6MWD or in symptomatology. Of note, two patients in the bosentan-treated group had increased requirements for supplemental oxygen. The number of patients enrolled and duration of follow-up were not sufficient to detect an effect on outcomes such as transplant-free survival or hospitalisations. Other studies have evaluated inhaled iloprost, intravenous prostacyclin and other PAH therapies [11–13], which have demonstrated improvement in right heart haemodynamics, with variable responses in 6MWD, symptoms and quality of life metrics. We are currently awaiting the results of a randomised-controlled trial looking at riociguat in treating patients with SaPH [12].

In this issue of the European Respiratory Journal, Shlobin et al. [14] describe physiologic prognostic factors in the ReSAPH registry, the largest cohort yet of patients (n=159) with RHC-confirmed pre-capillary pulmonary hypertension in the setting of sarcoidosis. Both incident and prevalent patients were included in this multinational registry, with incident patients defined as having a diagnosis of PH made less than 1 year prior to entry into the registry, and prevalent patients having been diagnosed more than 1 year prior to entry. For this study, PH was defined by the 2015 European Society of Cardiology/European Respiratory Society guidelines, as mPAP ≥25 mmHg [15]. Most SaPH patients had severe PH, with an average mPAP of 36.9±9.2 mmHg and pulmonary vascular resistance of 5.9±3.4 Wood units. The patients in this study had comparatively less severe haemodynamics than in the French cohort reported by Boucly et al. [8]. Similar to the French study, though, the vast majority (66%) had Scadding stage IV changes on radiogram and marked impairments in lung function were present with reduced FVC (62.4±19.7% predicted) and severely reduced diffusing capacity of the lung for carbon monoxide (DLCO) (40.0±15.9% predicted). Higher rates of transplant-free survival were observed in the prevalent group compared to the incident subgroup at all time points (1, 3 and 5 years), consistent with the known survivor bias observed in prevalent (versus incident) patients with group 1 PAH [16]. Transplant-free survival was associated with DLCO and 6MWD, which reached statistical significance both at prespecified cut-offs and on univariate analysis. In multivariate analysis there was an association between 6MWD and survival, however they also discovered an association between lower forced expiratory volume in 1 s to FVC ratio and improved outcomes, which was a novel and interesting finding.

In the context of the existing literature, several important insights into SaPH emerge from this large ReSAPH study. First, the 6MWD was independently associated with outcomes in the ReSAPH study [14] and in the French cohort studied by Boucly et al. [8], illustrating the power of this test as a global marker of impairment and disease severity in SaPH. Yet, there was no effect on 6MWD in the only randomised trial in this patient population, raising questions as to whether PAH therapies have any meaningful benefits on clinical outcomes or prognostic variables in SaPH [10]. There were no longitudinal data in the report of Shlobin et al. [14] to support the notion of treatment-related improvements in 6MWD or other clinical parameters. In the study by Boucly et al. [8], there were statistically significant improvements during follow-up in functional class and haemodynamics, but no improvement in 6MWD in the subgroup of patients treated with PAH therapies. Baseline haemodynamic parameters and use of PAH therapy were not related to transplant-free survival in the ReSAPH study; however, the treated subgroup had worse haemodynamics, raising the possibility that PAH therapy masked any association between haemodynamic severity and outcomes. Secondly, Shlobin et al. [14] confirmed the long latency to time of PH diagnosis. Boucly et al. [8] reported a mean time to diagnosis of PH from initial diagnosis of sarcoidosis of 17 years, and Shlobin et al. [14] have demonstrated a mean time to diagnosis of 12.6 years. This illustrates the importance of long-term follow-up of sarcoidosis patients to monitor for this late and serious complication. Thirdly, by including all-comers with SaPH, irrespective of PH severity at the time of initial diagnosis, the Shlobin et al. [14] study may be more generalisable than other large cohorts of SaPH. In contrast, the study of Boucly et al. [8] included only severe SaPH patients in their analysis, and Shorr et al. [3] included only sarcoidosis patients listed for lung transplant, who are a more severely afflicted population, by definition. Despite no severity threshold being set, the mPAP at the time of diagnosis in the ReSAPH study was 36.9 mmHg, highlighting the possibility that we are missing an opportunity to identify PH in this population earlier. Particularly when combined with the knowledge that the latency between sarcoidosis diagnosis and diagnosis of SaPH is greater than a decade, there are many years in which we could diagnose PH and potentially intervene at an earlier stage for these patients. Currently we lack studies showing an improvement in patient outcomes with earlier diagnosis and treatment of PH in sarcoidosis. However, it is possible that with proper characterisation of the underlying mechanisms of PH at earlier stages of disease, PAH therapies could benefit carefully selected patients. Lastly, the demonstration of airflow obstruction as an indicator of improved prognosis is hypothesis-generating from the perspective of how the mechanism of elevated pulmonary pressure relates to outcomes. It suggests that those with a predominantly bronchocentric pattern of fibrosis and a primarily obstructive ventilatory defect from greater small airways involvement may be at lower risk in the context of pre-capillary PH, compared to those with pulmonary artery compression by mediastinal disease or direct granulomatous vascular involvement. This result certainly warrants confirmation and further exploration in relation to computed tomography (CT) imaging features.

In light of these findings, it is clear that further work is needed to better characterise the different phenotypes of sarcoidosis that lead to SaPH. It is also clear that we need better ways of identifying PH before severe functional impairment develops. Based on the consistent association between 6MWD and outcomes in SaPH in two large registry-based studies, those with markedly reduced 6MWD deserve special attention, earlier consideration for haemodynamic assessment and consideration for lung transplantation referral. Further work is necessary to understand how the use of biomarkers, cardiac magnetic resonance imaging, alveolar–arterial oxygen gradient, desaturation on exertion, stress echocardiography, CT imaging characteristics and pulmonary function abnormalities (namely airflow obstruction and KCO) can be incorporated in a multi-modality risk assessment tool for SaPH, as has been the case for group 1 PAH. It will also be necessary to consider how the findings of these studies relate to the recent World Symposium on Pulmonary Hypertension task force proposal to revise the haemodynamic definition of PH from a mPAP ≥25 mmHg to >20 mmHg [7]. As our knowledge of SaPH phenotypes and prognostic factors advances, we may begin to better identify which patients might meaningfully respond to targeted treatment of their PH, which could ultimately inform the design of future randomised trials in this field. Until that time, we lack proof as to whether PAH therapies are “SaPHe” and whether they improve patient outcomes.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-00700-2020.Shareable

Footnotes

  • Conflict of interest: D. Vis has nothing to disclose.

  • Conflict of interest: A. Boucly reports personal fees and non-financial support from Actelion, personal fees from MSD, outside the submitted work.

  • Conflict of interest: M. Humbert reports personal fees from Acceleron, Merck, Morphogen IX and United Therapeutics, grants and personal fees from Actelion, Bayer and GSK, outside the submitted work.

  • Conflict of interest: J. Weatherald reports grants, personal fees and non-financial support from Janssen Inc. and Actelion, personal fees and non-financial support from Bayer, personal fees from Novartis, grants from Alberta Lung Association, Canadian Vascular Network, European Respiratory Society and Canadian Thoracic Society, outside the submitted work.

  • Received March 15, 2020.
  • Accepted March 16, 2020.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Baughman RP,
    2. Engel PJ,
    3. Taylor L, et al.
    Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138: 1078–1085. doi:10.1378/chest.09-2002
    OpenUrlCrossRefPubMed
    1. Handa T,
    2. Nagai S,
    3. Miki S, et al.
    Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129: 1246–1252. doi:10.1378/chest.129.5.1246
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Shorr AF,
    2. Helman DL,
    3. Davies DB, et al.
    Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25: 783–788. doi:10.1183/09031936.05.00083404
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Huitema MP,
    2. Bakker ALM,
    3. Mager JJ, et al.
    Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study. Eur Respir J 2019; 54: 1900897. doi:10.1183/13993003.00897-2019
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Huitema MP,
    2. Grutters JC,
    3. Rensing BJWM, et al.
    Pulmonary hypertension complicating pulmonary sarcoidosis. Netherlands Hear J 2016; 24: 390–399. doi:10.1007/s12471-016-0847-1
    OpenUrl
  5. ↵
    1. Nunes H,
    2. Humbert M,
    3. Capron F, et al.
    Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61: 68–74. doi:10.1136/thx.2005.042838
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Simonneau G,
    2. Montani D,
    3. Celermajer DS, et al.
    Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913. doi:10.1183/13993003.01913-2018
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Boucly A,
    2. Cottin V,
    3. Nunes H, et al.
    Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50: 1700465. doi:10.1183/13993003.00465-2017
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Sulica R,
    2. Teirstein AS,
    3. Kakarla S, et al.
    Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128: 1483–1489. doi:10.1378/chest.128.3.1483
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Baughman RP,
    2. Culver DA,
    3. Cordova FC, et al.
    Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 2014; 145: 810–817. doi:10.1378/chest.13-1766
    OpenUrlCrossRefPubMed
  10. ↵
    1. Baughman RP,
    2. Judson MA,
    3. Lower EE, et al.
    Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffus Lung Dis 2009; 26: 110–120.
    OpenUrl
  11. ↵
    1. Barnett CF,
    2. Bonura EJ,
    3. Nathan SD, et al.
    Treatment of sarcoidosis-associated pulmonary hypertension: a two-center experience. Chest 2009; 135: 1455–1461. doi:10.1378/chest.08-1881
    OpenUrlCrossRefPubMed
  12. ↵
    1. Bonham CA,
    2. Oldham JM,
    3. Gomberg-Maitland M, et al.
    Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest 2015; 148: 1055–1062. doi:10.1378/chest.14-2546
    OpenUrlCrossRefPubMed
  13. ↵
    1. Shlobin OA,
    2. Kouranos V,
    3. Barnett SD, et al.
    Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. Eur Respir J 2020; 55: 1901747. doi:10.1183/13993003.01747-2019
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Galiè N,
    2. Humbert M,
    3. Vachiery JL, et al.
    ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903–975. doi:10.1183/13993003.01032-2015
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Miller DP,
    2. Gomberg-Maitland M,
    3. Humbert M
    . Survivor bias and risk assessment. Eur Respir J 2012; 40: 530–532. doi:10.1183/09031936.00094112
    OpenUrlFREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 55 Issue 5 Table of Contents
European Respiratory Journal: 55 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?
Daniel Vis, Athénaïs Boucly, Marc Humbert, Jason Weatherald
European Respiratory Journal May 2020, 55 (5) 2000700; DOI: 10.1183/13993003.00700-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?
Daniel Vis, Athénaïs Boucly, Marc Humbert, Jason Weatherald
European Respiratory Journal May 2020, 55 (5) 2000700; DOI: 10.1183/13993003.00700-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Biomarkers in lung cancer screening
  • Household air pollution and adult respiratory health
  • Tobacco control and the ERS
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society